Skip to content

Using GLP-1s

Hazard ratio

A statistic from clinical trials that compares how often an event happens over time in one group versus another; below 1 means a lower rate in the treated group.

By the glp1.how editorial teamReviewed

A hazard ratio (HR) compares the rate at which an event, such as a heart attack or death, occurs over the course of a study in one group versus another, usually a treatment group versus placebo. An HR of 1.0 means no difference. An HR of 0.80 means the treated group had events at about 80% of the comparison group's rate, which is a 20% lower relative rate. An HR above 1 means a higher rate. For example, the SELECT trial reported an HR of 0.80 for major cardiovascular events with semaglutide versus placebo.

Always read the HR with its 95% confidence interval: if the interval crosses 1.0, the result isn't statistically significant. Remember too that a hazard ratio is a relative measure. A 20% reduction in a rare event prevents far fewer cases than a 20% reduction in a common one, so look for the absolute numbers as well. See every key GLP-1 clinical trial and the cardiovascular benefits of GLP-1 medications. SELECT trial: Lincoff et al., NEJM, 2023 (external link).

hazard-ratioclinical-trialsstatisticsevidenceglossary

Revision history

Updated 2 times since Sep 26, 2026 · show changes
  1. v3

    Body revised

  2. v2

    Published

  3. v1

    First version

Related guides

  • Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found · STEP 1, SURMOUNT-4, SELECT, LEADER: GLP-1 trial names get quoted everywhere, usually without context. This reference page lists 205 named, completed GLP-1 trials in one place, grouped by drug and by question, with what each one tested, who sponsored it, its headline result, and a link to the published paper. It also lists the trials that finished but have not reported, and shows who paid for the research.
  • GLP-1 myths vs. facts: what the media and social feeds get wrong · A plain-language, evidence-checked look at the most common claims about GLP-1 medications in the news and on social media: which are false, which are true, and which are still unsettled, with the studies behind each verdict.
  • The cardiovascular benefits of GLP-1 medications · Several GLP-1 medications have been tested in large cardiovascular outcomes trials, and they lowered the combined rate of heart attack, stroke and cardiovascular death. The pooled data show clear drops in cardiovascular death, heart attacks and heart failure, but not a clear drop in stroke. What the trials found, who was in them, and what they don't tell you.
  • Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis · GLP-1 medications slow the stomach, but the trials show the effect is smaller and fades more than most people assume, especially with the long-acting weekly drugs. This guide covers how much slower, whether it lasts, how gastric emptying is measured, how it differs from gastroparesis, and why the "food ferments in your stomach" claim has no evidence behind it.
  • Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration · Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
  • Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo · There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.

Related terms

  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.

Was this helpful?

Improve this page